SR1 assays of alpha-fetoprotein, carcinoembryonic antigen, and prostate-specific antigen compared with corresponding established commercial assays.
We compared results obtained with the newly developed alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), and prostate-specific antigen (PSA) assays for the fully-automated Serono SR1 analyzer with those obtained with the major, established methods for these analytes: Serono Serozyme and Bridge, Abbott IMx, Kodak Amerlite, Boehringer Mannheim ES600, Pharmacia Delfia, Hybritech Tandem-E and Tandem-R, Ciba Corning ACS180, and DPC IRMA-Count. The correlations were good for all methods studied (r > or = 0.94). For AFP, numerical agreement was good, with linear regression slopes of 0.88 to 1.15; for CEA, correlation slopes of 1.03 to 1.16 were observed. The SR1 PSA assay agreed well with five of the seven methods studied (slopes of 0.98 to 1.22), but the Ciba Corning ACS180 PSA assay gave results higher than all other methods studied (slope 0.54 vs SR1 at low doses) and the Abbott IMx PSA assay gave results lower than all other methods studied (slope 1.47 vs SR1).
Jolley
N L
NL
Serono Diagnostics Ltd., Woking, Surrey, UK.
Bacarese-Hamilton
T
T
D001322:Autoanalysis / Q000295:instrumentation; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D002624:Chemistry, Clinical / Q000295:instrumentation* / Q000379:methods; D006801:Humans; D017430:Prostate-Specific Antigen / Q000097:blood*; D011933:Reagent Kits, Diagnostic; D012044:Regression Analysis; D000509:alpha-Fetoproteins / Q000032:analysis*
D002272:Carcinoembryonic Antigen; D011933:Reagent Kits, Diagnostic; D000509:alpha-Fetoproteins; D017430:Prostate-Specific Antigen